Anavex Life Sciences Corp (AVXL)

[pcguy]

Assessing How Much an Alzheimer’s Drug is Worth

Summary of the Event Studies

"Based on the event studies on Biogen’s Aducanumab and Lilly’s Donanemab, the value of a drug candidate at or ready for Phase 3 trial would be worth $20.2 billion to $20.7 billion, and a Breakthrough Therapy Designation has a value of $13.4 billion. An Alzheimer’s drug approved by the FDA carries a market value of $43.4 billion."

https://www.ipwatchdog.com/2021/10/26/assessing-much-alzheimers-drug-worth/id=139154/